Source - SMW
Doug Doerfler, President & CEO of MaxCyte (MXCT) (LSE:MXCT) will be giving a briefing at the Shares Investor Evening on 27th September 2016. It will take place in London at an investor evening being organised by Shares magazine; the event is supported by AJ Bell Youinvest. 

MaxCyte is a leader in cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is focused in applying its significant capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of chronic and acute diseases. MaxCyte's customers and partners utilize its technologies in the development and commercialization of cell-based therapies in regenerative medicine and active cell immunotherapies and in the discovery and development of protein drugs, monoclonal antibodies, vaccines, and small molecule drugs.

The Shares event offers a unique opportunity to hear about the latest plans and strategy from the Directors of UK listed companies and Fund Managers, attendees can personally put forward questions to the presenters. The event will take place at the Novotel Tower Bridge, 10 Pepys Street, London EC3N 2NR. Registration begins at 17:15 and presentations at 17.45, followed by a drinks reception where attendees can mingle with the speakers and fellow investors.

Companies presenting at the event include:

Allergy Therapeutics (AGY)


Central Asia Metals (CAML)

MaxCyte (MXCT)

Palace Capital (PCA)

Real Good Food (RGD)

Investors can register now for free at:

At 3:46pm: (LON:MXCT) Maxcyte Inc share price was 0p at 84.5p